Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense remains negative
Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0. Over 3 fiscal years it compounded at -10.3% a year.
Context
- Income tax expense amounted to 0.2% of revenue in FY2025, down 0.5 pp from a year earlier.
- Income tax expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 106K USD
- Year-over-year change
- -71.0%
- 4-year CAGR
- -0.9%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 106K | -71.0% |
| FY2024 | 2024-12-31 | 365K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 147K | +33.6% |
| FY2021 | 2021-12-31 | 110K | — |
Income Tax Expense vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -100.0% is the 6th highest of 7, against a peer median of -17.4%.
- Income tax expense amounts to 0.0% of revenue for FRX.TO, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.02M USD | +30.6% | — | 11.1% | |
| LTM Mar 2026 | $10.69M USD | +267.5% | -1.0% | 3.5% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $234.65K USD | — | -3.7% | 1.3% |
| LTM Mar 2026 | $28.82K USD | +200.2% | — | — | |
| LTM Mar 2026 | CA$23K CAD | -99.7% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | -10.3% | 0.0% | |
| LTM Apr 2026 | -CA$43K CAD | -65.4% | — | — | |
| LTM Mar 2026 | -CA$13.66M CAD | -17878.9% | — | 5.0% | |
| Peer median (excluding FRX.TO) | — | -17.4% | -2.3% | 3.5% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 254.38K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.04M | 32.76M | 41.79M | 47.22M |
| Depreciation & Amortization | 17.22M | 149K | 287K | 800K | 103K |
| EBITDA | (17.19M) | (22.74M) | (12.65M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1481.2% | -59.5% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.59M) | (12.77M) | 2.57M | (6.35M) |
| Operating Margin | — | -1471.6% | -60.1% | 5.4% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.68M | 800.78K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.18M |
| Other Income / Expenses | (123K) | (1.13M) | (3.27M) | (2.64M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 110K | 147K | 0 | 365K | 106K |
| Net Income | (17.46M) | (23.86M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1554.5% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.91) | (0.60) | (0.02) | (0.34) |
| EPS (Diluted) | (0.67) | (0.91) | (0.60) | (0.02) | (0.34) |
| Weighted Avg Shares | 25.89M | 26.28M | 26.57M | 21.8M | 28.58M |
| Weighted Avg Shares (Diluted) | 26.01M | 26.28M | 26.57M | 27.3M | 28.58M |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.